Fate Therapeutics completes $100M share offering with institutional investors' participation.
Fate Therapeutics, a clinical-stage biopharmaceutical firm, announced a $100M underwritten offering of 14.54M shares at $5.50 each. Institutional investors including Adage Capital, Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital, and a life-sciences investor participated. Concurrently, a private placement of pre-funded warrants to purchase 3.63M shares was priced at $5.499 each.
March 19, 2024
5 Articles